T Cell Therapy of Opportunistic Cytomegalovirus Infection (NCT02982902)
Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).
Who can join: Review the eligibility criteria below.
Location: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Age range: 3 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (800) 641-2422
Email: CTUReferral@UHhospitals.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cytomegalovirus Infections
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation — Phoenix, Arizona
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients — Boston, Massachusetts
- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients — Houston, Texas
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients — Philadelphia, Pennsylvania
Explore by condition: All Cytomegalovirus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.